Expected Moves

The Read: Historically, RCUS stock has shown mixed volatility around FDA-related catalysts, with moderate moves of about 3% to 17% driven primarily by clinical data updates and financial results rather than FDA approvals, as seen in June 2026 when lackluster TIGIT/PD-1 combo data and strategic collaborations caused declines despite partnerships, indicating that FDA approval expectations have not triggered large positive jumps.